Arrayit Diagnostics, Inc. Reports Results of Research Study for Ovarian Cancer Diagnostic Test
"
Arrayit Corporation
and Arrayit Diagnostics, Inc. ("AD") report significant results from a
257 patient research study on its pre-symptomatic ovarian cancer
molecular diagnostic test in development, OvaDx(R). In this study,
OvaDx(R) recorded sensitivity of 79.7%, correctly identifying patients
known to have cancer, and specificity approaching 100%, correctly
identifying the healthy controls, patients known not to have cancer......
An ovarian cancer blog which includes quality resource materials: education, research, social networking, genetics and (some) healthcare politics.
“Not everything that can be counted counts and not everything that counts can be counted.”
Albert Einstein
No comments:
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.